Products Categories
| CAS No.: | 163222-33-1 |
|---|---|
| Name: | Ezetimibe |
| Molecular Structure: | |
|
|
|
| Formula: | C24H21F2NO3 |
| Molecular Weight: | 409.432 |
| Synonyms: | (-)-Sch 58235;Zetia (TN);Zetia;Ezetimibe 1-(4-flurophenyl)-(3R)-[3-(4-flurophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone;2-Azetidinone,1-(4-fluorophenyl)-3-[(3S)-3- (4-fluorophenyl)-3-hydroxypropyl]-4-(4- hydroxyphenyl)-,(3R,4S)-;Sch 58235;Vytorin;Ezedoc;(3R,4S)-1-(4-Fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone; |
| EINECS: | 682-606-0 |
| Density: | 1.334 g/cm3 |
| Melting Point: | 164-166 °C |
| Boiling Point: | 654.9 °C at 760 mmHg |
| Flash Point: | 349.9 °C |
| Appearance: | white powder |
| Hazard Symbols: | R36/37/38:; |
| Risk Codes: | 36/37/38 |
| Safety: | 26-36 |
| PSA: | 60.77000 |
| LogP: | 4.95330 |
- 483366-12-7(2S,4R)-1-Boc-2-cyano-4-hydroxypyrrolidine
- 173606-50-3BOC-10-AMINODECANOIC ACID
- 361456-36-2METHYL (R)-(+)-ISOCYANATO-3-PHENYLPROPI&
- 5156-58-1N-(1-Benzyl-4-pipperidinyl)-N-phenylpropanamide HCl
- 81281-59-67-Benzylideneaminotheophylline
- 50288-62-5threo-Phenyl-2-piperidyl acetamide
- 82993-81-5D-threo-Ritalinic acid hydrochloride
- 47087-37-6Z-D-Glu-OMe
- 73441-42-6METHYL-5-CHLORO-2,2-DIMETHYLVALERATE
- 211914-50-0N-[[2-[[[4-(Aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-(2-pyridinyl)-beta-alanine ethyl ester hydrochloride
- 163222-32-0
(3R,4S)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4-(4-benzyloxyphenyl)-2-azetidinone
- 163222-33-1
ezetemibe
| Conditions | Yield |
|---|---|
| With 10 wt% Pd(OH)2 on carbon; hydrogen In methanol; cyclohexane at 70℃; under 760.051 Torr; for 3h; | 99% |
| With 5%-palladium/activated carbon; hydrogen In tetrahydrofuran; ethanol at 50 - 55℃; under 37.5038 - 75.0075 Torr; | 90.3% |
| With palladium 10% on activated carbon; ammonium formate; acetic acid for 6h; Reflux; | 90% |
- 873205-85-7
1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone hydrate
- 163222-33-1
ezetemibe
| Conditions | Yield |
|---|---|
| In n-heptane; tert-butyl methyl ether at 20℃; Product distribution / selectivity; Heating / reflux; | 99% |
| In Isopropyl acetate at 20℃; Product distribution / selectivity; Heating / reflux; | |
| With acetic acid at 20℃; Product distribution / selectivity; Heating / reflux; |
- 163222-33-1
ezetemibe
| Conditions | Yield |
|---|---|
| With sulfuric acid In water; isopropyl alcohol at 20 - 25℃; for 1h; | 95% |
| With perchloric acid at 40℃; for 3h; Temperature; Solvent; | 92% |
| With sulfuric acid In water; isopropyl alcohol at 20℃; for 1h; | 91.5% |
- 163222-33-1
ezetemibe
| Conditions | Yield |
|---|---|
| With pyridine hydrofluoride In tetrahydrofuran; pyridine at 20℃; for 24h; | 93% |
- 1232148-26-3
4-((2S,3R)-1-(4-fluorophenyl)-3-((S)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-oxoazetidin-2-yl)phenyl pivalate
- 163222-33-1
ezetemibe
| Conditions | Yield |
|---|---|
| Stage #1: 4-((2S,3R)-1-(4-fluorophenyl)-3-((S)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-oxoazetidin-2-yl)phenyl pivalate With sodium hydroxide In tetrahydrofuran; methanol at -15℃; Stage #2: With hydrogenchloride; water In ethyl acetate | 92% |
- 163222-33-1
ezetemibe
| Conditions | Yield |
|---|---|
| With N,O-bis-(trimethylsilyl)-acetamide; tetrabutyl ammonium fluoride In tert-butyl methyl ether at 20℃; for 0.25h; | 91% |
- 191330-56-0
[14C]-Sch 57871
- 163222-33-1
ezetemibe
| Conditions | Yield |
|---|---|
| With dimethylsulfide borane complex; trifluoroacetic anhydride; (3aR)-1-methyl-3,3-diphenyl-tetrahydro-pyrrolo[1,2-c][1,3,2]oxazaborole In dichloromethane; toluene at -25 - -20℃; for 3h; Inert atmosphere; | 90% |
| With glucose dehydrogenase; alpha-D-glucopyranose; NADP; KRED-128 In water; isopropyl alcohol at 35℃; for 1.5h; pH=7; Product distribution / selectivity; Phosphate buffer; | 89.26% |
| With glucose dehydrogenase; potassium phosphate; alpha-D-glucopyranose; DL-dithiothreitol; NADP; magnesium sulfate; KRED-118 In methanol; water at 30℃; pH=7.0; Product distribution / selectivity; | 87.59% |
- 163222-33-1
ezetemibe
| Conditions | Yield |
|---|---|
| With hydrogen bromide In isopropyl alcohol at 20℃; for 4h; | 87% |
- 1004520-48-2
(3R,4S)-1-(4-fluorophenyl)-3-((S)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)azetidin-2-one
- 163222-33-1
ezetemibe
| Conditions | Yield |
|---|---|
| With dihydrogen peroxide In acetic acid at 20℃; for 2h; Time; | 86.23% |
| With dihydrogen peroxide In water; isopropyl alcohol at 20℃; for 0.5h; |
- 163222-33-1
ezetemibe
| Conditions | Yield |
|---|---|
| With palladium on activated charcoal; hydrogen; acetic acid In ethanol at 25℃; for 4h; pH=3; | 85.4% |
- 138112-76-2Agomelatine
- 654671-77-9Sitagliptin phosphate monohydrate
- 274901-16-52-Pyrrolidinecarbonitrile,1-[2-[(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]-, (2S)-
- 102767-28-2Levetiracetam
- 137234-62-9Voriconazole
- 73-22-3L-Tryptophan
- 202138-50-9Tenofovir disoproxil fumarate
- 8013-07-8Soybean oil, epoxidized
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
What can I do for you?
Get Best Price
Chemistry
Name: Ezetimibe
Synonyms: 1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxy-propyl]-4-(4-hydroxyphenyl)-azetidin-2-one
CAS Registry Number: 163222-33-1
Molecular Formula: C24H21F2NO3
Molecular Weight: 409.43
Molecular Structure: 
Mp: 164-166°C
Uses
Ezetimibe is an anti-hyperlipidemic medication which is used to lower Cholesterol levels. It acts by decreasing Cholesterol absorption in the intestine. It could be used alone when other Cholesterol-lowering medications are not tolerated, or when Cholesterol levels are unable to be controlled on statins alone, ezetimibe could be used together with statins
Safety Profile
Risk Statements: 36/37/38
R36/37/38:Irritating to eyes, respiratory system and skin.
Safety Statements: 26-36
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
S36:Wear suitable protective clothing.
Use cautiously in:
1)breastfeeding patients
2)children younger than age 10
3)pregnant patients not receiving HMG-CoA reductase inhibitors
4)renal or hepatic impairment
5)elderly patients.
Specification
Patient monitoring:
1)Monitor hepatic and lipid profiles
2)Assess for and report unexplained muscle pain.